The FDA enforcement report dated 14 October lists a Class II recall of compounded tirzepatide with cyanocobalamin, 26/2 mg/mL in single-use syringes, from Carolina Infusion, a US compounding pharmacy. The reason given is lack of sterility assurance, linked to the use of bacteriostatic water and to processing equipment. The recall is ongoing, and related semaglutide products from the same firm are also listed.
This is a quality action on compounded products, not a finding about licensed tirzepatide. It matters to prescribers because compounded and online incretins, often combined with vitamins, are widely used and are not held to the same manufacturing standards.
- Ask patients where their tirzepatide or semaglutide comes from.
- Syringe packs and vitamin combinations indicate a compounded, not a licensed, product.
- Report suspected adverse reactions to compounded products to pharmacovigilance.
- The recall affects one US compounder's products only.
Why it matters
Unlicensed incretin supply is large, and its quality failures reach patients directly.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free